Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 11/20 | 0.78 |
| ▸ | VEGFA | P15692 | 10/20 | 0.78 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | BACE1 | P56817 | 4/20 | 0.45 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272935 | 0.88 | EGLN1 (1.00) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL278141 | 0.87 | EGLN1 (0.79) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL271477 | 0.85 | VEGFA (0.76) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL19478697 | 0.84 | EGLN1 (0.78) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL278211 | 0.83 | VEGFA (0.75) | EGLN1VEGFAKDM4EALDH1A1 | |
| SCHEMBL272882 | 0.81 | VEGFA (0.70) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL30274325 | 0.79 | EGLN1 (0.69) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL21667234 | 0.76 | VEGFA (0.62) | EGLN1VEGFAACHEBACE1BCHE | |
| SCHEMBL272670 | 0.76 | EGLN1 (0.88) | EGLN1VEGFAKDM4EALDH1A1TP53 | |
| SCHEMBL12649394 | 0.76 | VEGFA (0.70) | EGLN1VEGFAACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885ACHE 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.